Zoe Quandt, MD

Assistant Prof in Residence
M_Diabetes Center

Dr. Quandt is an endocrinologist at UCSF and the San Francisco VA with particular interest in endocrine autoimmune disease like type 1 diabetes and endocrine complications of cancer treatments, particularly immunotherapy. She does clinical and translational research trying to better understand who gets these complications and why. She is the clinical lead for adults eligible for teplizumab, an immunotherapy approved to delay the onset of type 1 diabetes.

Publications

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.

Journal of diabetes science and technology

Mader JK, Wong JC, Freckmann G, Garcia-Tirado J, Hirsch IB, Johnson SB, Kerr D, Kim SH, Lal R, Montaser E, O'Donnell H, Pleus S, Shah VN, Ayers AT, Ho CN, Biester T, Dovc K, Farrokhi F, Fleming A, Gillard P, Heinemann L, López-Díez R, Maahs DM, Mathieu C, Quandt Z, Rami-Merhar B, Wolf W, Klonoff DC

HLA associations with immunotherapy related endocrine toxicity.

Journal of Clinical Oncology

Zoe Quandt, Christian Thorball, Pooja Middha, Douglas Buckner Johnson, Cosmin A Bejan, Lydia Yao, Yaomin Xu, Flavia Hodel, Athina Stravodimou, Esther Shearer-Kang, Geoffrey Liu, Melinda C Aldrich, Adam Jacob Schoenfeld, Elad Ziv, Elizabeth J Phillips, Jacques Fellay, Ewa A Bergmann, G Scott Chandler, Justin M Balko, Ashis Saha

Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq.

eLife

Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY, Tagi VM, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kämpe O, Dobbs K, Delmonte OM, Bacchetta R, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder